Lifespan of middle-aged mice increased by a third with telomerase gene therapy
CISION PR Newswire - 19-May-2022Treatment used proprietary CMV vector which is able to deliver multiple genes into the nucleus
Join the club for FREE to access the whole archive and other member benefits.
Gene therapy innovation leaders developing platforms to treat severe genetic disorders and cellular aging
BioViva USA Inc is dedicated to improving healthy human longevity through gene therapy.
BIOVIVA'S patent pending technology will revolutionize gene therapy delivery. Our bioinformatics platform and the BioKeeper™ Vault will contribute to health predictions and recommendations, precision medicine, and the discovery of novel biomarkers. Helping us create even better therapies for you in the future!
Look for the first, easy to use, data base for disease specific information coming soon. BioViva will soon be welcoming the CodeKeeper™! A powerful tool to put open source genetics into your hands.
Visit website: https://bioviva-science.com/
Details last updated 04-Feb-2019
Liz Parrish discusses the latest advancements in human gene therapy
Dr. Andrews of Sierra Sciences discusses aging, telomeres, and treatment hurdles
Treatment used proprietary CMV vector which is able to deliver multiple genes into the nucleus
Approaches include senotherapeutics, stem cells and mitochondria. Eye disease is a common first target.
Evident reversal of Dementia symptoms sustained cognitive improvement
Launched home test to track biological age; outcomes of unlicensed gene-therapy are yet to report
Interesting articles and some useful investment opportunities
Most age related diseases are a symptom of cellular malfunction. Gene therapy allows us to repla...
75 potential targets for gene therapy in the near future. Rapid advances in genetic editing tech...
First company to treat a person with gene therapy to reverse biological aging. Patient to be mon...
Gene therapies Stem cell therapies Enhancing native stem cell activities Thymus restoration I...